Brain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) after Intranasal Administration

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2004-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/JPET.103.063222PMID 14724226
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat

  2004cited by this paper
• The glucagon-like peptides: a double-edged therapeutic sword?

  2003cited by this paper
• Entry of exendin-4 into brain is rapid but may be limited at high doses

  2003influential reference
• Passage of vasoactive intestinal peptide across the blood-brain barrier.

  2003cited by this paper
• Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

  2003influential reference
• Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats.

  2003cited by this paper
• Positron emission tomography shows that intrathecal leptin reaches the hypothalamus in baboons.

  2002cited by this paper
• Sniffing neuropeptides: a transnasal approach to the human brain

  2002cited by this paper
• Differential Transport of a Secretin Analog across the Blood-Brain and Blood-Cerebrospinal Fluid Barriers of the Mouse

  2002cited by this paper
• The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease

  2002cited by this paper
• Central nervous system effects of intranasally administered insulin during euglycemia in men.

  1999cited by this paper
• Contribution of extracranial lymphatics and arachnoid villi to the clearance of a CSF tracer in the rat.

  1999influential reference
• Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin.

  1997cited by this paper
• Periventricular penetration and disappearance of ICV Tyr-MIF-1, DAMGO, tyrosine, and albumin.

  1996cited by this paper
• Physiology and immunology of lymphatic drainage of interstitial and cerebrospinal fluid from the brain

  1995cited by this paper
• Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier.

  1993cited by this paper
• Murine tumor necrosis factor alpha is transported from blood to brain in the mouse.

  1993cited by this paper
• CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance

  1993cited by this paper
• Use of 2-hydroxypropyl-beta-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs.

  1991cited by this paper
• Use of 2-Hydroxypropyl-β-cyclodextrin as a Solubilizing and Stabilizing Excipient for Protein Drugs

  1991cited by this paper
• Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins

  1990cited by this paper
• Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey

  1986cited by this paper
• Endocytic and exocytic pathways of the neuronal secretory process and trans synaptic transfer of wheat germ agglutinin‐horseradish peroxidase in vivo

  1985cited by this paper

• Advanced intranasal peptide delivery systems for improved management of Alzheimer's disease.

  2025cites this paper
• Albumin antagonizes Alzheimer's disease-related Tau pathology and enhances cognitive performance by inhibiting aberrant Tau aggregation.

  2025cites this paper
• Modulation of antibody transport in the brain and spinal cord through the intranasal pathway

  2025cites this paper
• Physiological Effects of Modified Obestatin Analogues in Rats

  2025cites this paper
• ORAL OR INTRANASAL ANGIOTENSIN-(1-7) IMPROVES ANXIETY AND DEPRESSION-LIKE BEHAVIORS IN MICE SUBJECTED TO ALLERGIC PULMONARY INFLAMMATION.

  2025cites this paper
• An Update on Recent Drug Delivery Systems Targeting Brain Diseases via the Transnasal Pathway

  2024cites this paper
• Recent advances in intranasal delivery of therapeutic peptides

  2024cites this paper
• Lipid nanocapsules: A Novel Strategy for Brain Targeting via Nasal Administration

  2024cites this paper
• Optimizing nasal drug delivery for peptides, proteins, and small molecules: strategic use of materials and techniques to target the CNS

  2024cites this paper
• Local Delivery Strategies for Peptides and Proteins into the CNS: Status Quo, Challenges, and Future Perspectives

  2023cites this paper
• Nose-to-Brain (N2B) Delivery: An Alternative Route for the Delivery of Biologics in the Management and Treatment of Central Nervous System Disorders

  2023cites this paper
• Cell-Penetrating Peptides as Valuable Tools for Nose-to-Brain Delivery of Biological Drugs

  2023cites this paper
• Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson's disease.

  2023cites this paper
• Intranasal Fentanyl for Acute Pain Management in Children, Adults and Elderly Patients in the Prehospital Emergency Service and in the Emergency Department: A Systematic Review

  2023cites this paper
• Current state of phoenixin—the implications of the pleiotropic peptide in stress and its potential as a therapeutic target

  2023cites this paper
• Intranasal Administration of Resolvin E1 Produces Antidepressant-Like Effects via BDNF/VEGF-mTORC1 Signaling in the Medial Prefrontal Cortex

  2023cites this paper
• Vaginal epithelial drug delivery.

  2022cites this paper
• Nose-to-brain drug delivery for the treatment of Alzheimer’s disease: current advancements and challenges

  2022cites this paper
• Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Neuroinflammation: Implications for Neurodegenerative Disease Treatment.

  2022cites this paper
• The Novel Peptide Chm-273s Has Therapeutic Potential for Metabolic Disorders: Evidence from In Vitro Studies and High-Sucrose Diet and High-Fat Diet Rodent Models

  2022cites this paper
• Biodistribution analysis of an intranasal-delivered peptide by the nanoSPECT/CT imaging

  2022cites this paper
• Failure of the Brain Glucagon-Like Peptide-1-Mediated Control of Intestinal Redox Homeostasis in a Rat Model of Sporadic Alzheimer’s Disease

  2021cites this paper
• A REVIEW ON NOSE TO BRAIN DRUG DELIVERY SYSTEM

  2021cites this paper
• Intranasal administration of mitochondria improves spatial memory in olfactory bulbectomized mice

  2021cites this paper
• Intranasal drug delivery for treatment of Alzheimer’s disease

  2021cites this paper
• Improving the Utility of a Dynorphin Peptide Analogue Using Mannosylated Glycoliposomes

  2021cites this paper
• Intranasal insulin and orexins to treat age-related cognitive decline.

  2021cites this paper
• Investigation of the Transport Pathways Associated with Enhanced Brain Delivery of Peptide Drugs by Intranasal Coadministration with Penetratin

  2021cites this paper
• Formulation strategies for nose-to-brain delivery of therapeutic molecules

  2020cites this paper
• Liraglutide mends cognitive impairment by averting Notch signaling pathway overexpression in a rat model of polycystic ovary syndrome.

  2020cites this paper
• Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.

  2020cites this paper
• Intranasal Delivery: Effects on the Neuroimmune Axes and Treatment of Neuroinflammation

  2020cites this paper
• The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration

  2019cites this paper
• Intranasal administration of progesterone: A potential efficient route of delivery for cerebroprotection after acute brain injuries

  2019cites this paper
• Mitral cells and the glucagon‐like peptide 1 receptor: The sweet smell of success?

  2019cites this paper
• Therapeutic Intranasal Delivery for Stroke and Neurological Disorders

  2019cites this paper
• Therapeutic Potential of Intranasal Drug Delivery in Preclinical Studies of Ischemic Stroke and Intracerebral Hemorrhage

  2019cites this paper
• Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia

  2019cites this paper
• The neuroprotective effect and action mechanism of polyphenols in diabetes mellitus-related cognitive dysfunction

  2019cites this paper
• Leserbrief zum Artikel: M. Müller, R. Löb: Medikamentenapplikation im akuten epileptischen Anfall des Kindes. Notarzt 2019; 35: 119 – 121

  2019cites this paper
• Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain.

  2019cites this paper
• Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency.

  2019cites this paper
• Drug targeting strategies into the brain for treating neurological diseases.

  2019cites this paper
• Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques.

  2018cites this paper
• Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality?

  2018cites this paper
• Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies

  2018cites this paper
• Neuroprotection of rhGLP‐1 in diabetic rats with cerebral ischemia/reperfusion injury via regulation of oxidative stress, EAAT2, and apoptosis

  2018cites this paper
• Intranasale Medikamentengabe im Rettungsdienst

  2018cites this paper
• Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world.

  2018cites this paper
• Assessing the feasibility of intranasal radiotracer administration for in brain PET imaging

  2018cites this paper
• Endogenous GLP‐1 alters postprandial functional connectivity between homeostatic and reward‐related brain regions involved in regulation of appetite in healthy lean males: A pilotstudy

  2018cites this paper
• Brain-Targeting Delivery of Two Peptidylic Inhibitors for Their Combination Therapy in Transgenic Polyglutamine Disease Mice via Intranasal Administration.

  2018cites this paper
• INTRANASAL DRUG DELIVERY-NEW CONCEPT OF THERAPEUTIC IMPLICATIONS FOR EFFECTIVE TREATMENT OF CNS DISORDERS

  2017cites this paper
• From Nose to Brain: The Promise of Peptide Therapy for AlzheimerâÂÂsDisease and Other Neurodegenerative Diseases

  2017cites this paper
• Numerical Comparison of Nasal Aerosol Administration Systems for Efficient Nose-to-Brain Drug Delivery

  2017cites this paper
• Nose-to-brain peptide delivery - The potential of nanotechnology.

  2017cites this paper
• Intranasal delivery of antipsychotic drugs.

  2017cites this paper
• Nanotherapeutics_ An insight into healthcare and multi-dimensional applications in medical sector of the modern world

  2017cites this paper
• Lipid Nanoparticles for Nasal/Intranasal Drug Delivery.

  2017cites this paper
• Smell and Taste Dysfunction Is Associated with Higher Serum Total Cholesterol Concentrations in Chinese Adults.

  2017cites this paper
• Dabigatran ameliorates post-haemorrhagic hydrocephalus development after germinal matrix haemorrhage in neonatal rat pups

  2017cites this paper
• LARETH-25 and β-CD improve central transitivity and central pharmacological effect of the GLP-2 peptide.

  2016cites this paper
• Calcium Carbonate-Based Mucoadhesive Microcontainers for Intranasal Delivery of Drugs Bypassing the Blood–Brain Barrier

  2016cites this paper
• Visualization and Quantitative Assessment of the Brain Distribution of Insulin through Nose-to-Brain Delivery Based on the Cell-Penetrating Peptide Noncovalent Strategy.

  2016cites this paper
• Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea.

  2016cites this paper
• Metabolic responses to xenin-25 are altered in humans with Roux-en-Y gastric bypass surgery.

  2016cites this paper
• Neuroprotective Effects of rhGLP‐1 in Diabetic Rats with Cerebral Ischemia/Reperfusion Injury

  2016cites this paper
• Controlled‐Release Technology: Pharmaceutical

  2016cites this paper
• Small intestinal targets involved in food intake regulation : 'from nutrient to satiety signal'

  2016cites this paper
• Role of functionalized liposomes in drug delivery through the blood-brain barrier

  2016cites this paper
• Therapeutic targets for Alzheimer's disease: Insights from in vitro and in vivo models of inflammation

  2016cites this paper
• Calcium Carbonate-Based Mucoadhesive Microcontainers for Intranasal Delivery of Drugs Bypassing the Blood–Brain Barrier

  2016cites this paper
• Translational and therapeutic potential of oxytocin as an anti-obesity strategy: Insights from rodents, nonhuman primates and humans.

  2015cites this paper
• Brain reward‐system activation in response to anticipation and consumption of palatable food is altered by glucagon‐like peptide‐1 receptor activation in humans

  2015cites this paper
• Novel Delivery Systems for Improving the Clinical Use of Peptides

  2015cites this paper
• Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans

  2015cites this paper
• Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases

  2015cites this paper
• Diabetes Mellitus, Cognitive Impairment, and Traditional Chinese Medicine

  2015cites this paper
• Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice.

  2015cites this paper
• Safety and efficacy of intranasally administered medications in the emergency department and prehospital settings.

  2015cites this paper
• Cholecystokinin regulates satiation independently of the abdominal vagal nerve in a pig model of total subdiaphragmatic vagotomy.

  2015cites this paper
• Intranasal Delivery to the Central Nervous System

  2015cites this paper
• Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides.

  2015cites this paper
• Intranasal Glucagon

  2014cites this paper
• Hindbrain oxytocin receptors contribute to the effects of circulating oxytocin on food intake in male rats.

  2014cites this paper
• Agile delivery of protein therapeutics to CNS.

  2014cites this paper
• Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic

  2014cites this paper
• Intranasal Administration as a Route for Drug Delivery to the Brain: Evidence for a Unique Pathway for Albumin

  2014cites this paper
• Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury

  2014cites this paper
• Brain dysfunction and cell death in type 2 diabetes : A neuroprotective role for the peripheral treatment with Exendin-4

  2014cites this paper
• Galanin-like Peptide Ameliorates Obesity by Control of Food Intake andEnergy Metabolism

  2014cites this paper
• Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System

  2014cites this paper
• Antidiabetic treatment, stroke severity and outcome.

  2014cites this paper
• Improved brain uptake of peptide-based CNS drugs via alternative routes of administrations of its nanocarrier delivery systems: a promising strategy for CNS targeting delivery of peptides

  2014cites this paper
• GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans

  2014cites this paper
• Incretin mimetics as pharmacological tools to elucidate and as a new drug strategy to treat traumatic brain injury

  2014cites this paper
• Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia.

  2014cites this paper
• Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration.

  2013cites this paper
• Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting

  2013influential citation
• Exenatide as a novel treatment for Parkinson's Disease

  2013cites this paper